Welcome to our dedicated page for Moolec Science news (Ticker: MLEC), a resource for investors and traders seeking the latest updates and insights on Moolec Science stock.
Moolec Science SA (NASDAQ: MLEC) generates news at the intersection of food-tech, life sciences, and agricultural biotechnology. The company regularly issues updates on how it engineers plants and microbes to produce animal proteins, nutritional oils, bioactive compounds, and biological inputs for regenerative agriculture through its Molecular Farming and precision fermentation platforms.
News about Moolec often covers progress in its key ingredient programs, such as its GLASO safflower technology enriched in gamma-linolenic acid and its Piggy Sooy™ soybean platform engineered to express porcine hemeproteins. Press releases have highlighted regulatory approvals, including feed and food approval for GLASO technology in Argentina and U.S. regulatory milestones for Piggy Sooy™, as well as large-scale agricultural campaigns and acreage expansion in the United States.
Investors and industry observers can also find coverage of Moolec’s corporate and strategic developments. Recent announcements include the closing of a strategic business combination with Bioceres Group Limited, Gentle Technologies Corp, and Nutrecon LLC, which expanded Moolec’s activities into ag-biologicals, biomaterials, and R&D services. The company also reports on the integration of Mycofood™, its fungal-based alternative protein platform produced via precision fermentation.
Moolec’s news flow additionally includes capital markets and compliance updates, such as Nasdaq determination letters related to minimum bid price, stockholders’ equity, and filing timelines, as well as share consolidations and reverse stock splits intended to support continued listing on the Nasdaq Capital Market. For readers tracking MLEC, this news page provides a centralized view of operational milestones, regulatory events, strategic transactions, and listing-related actions that shape the company’s trajectory in the food-tech and life sciences sectors.
Moolec Science (NASDAQ:MLEC) received a Nasdaq determination letter dated November 24, 2025, stating the company is not in compliance with Nasdaq Listing Rule 5250(c)(1) for failing to file its Annual Report on Form 20-F for year ended June 30, 2025 with the SEC.
The company attributed the delay to post-closing complexities from a mid-June 2025 business combination that triggered reverse acquisition accounting and valuation work. Moolec filed a Form 12b-25 on October 31, 2025, and requested a stay of suspension; the stay remains in effect pending a Nasdaq Hearings Panel hearing scheduled for December 18, 2025. Ordinary shares will continue trading on The Nasdaq Capital Market under the symbol MLEC during the stay. The company expects to file the Form 20-F before the hearing.
Moolec Science (NASDAQ:MLEC) received a Nasdaq determination letter dated November 14, 2025, notifying the company that its closing bid price had been below the $1.00 minimum for the last 30 consecutive business days under Nasdaq Listing Rule 5550(a)(2).
The letter indicated Nasdaq's view that the company would not receive an automatic 180-day compliance period. Moolec submitted a timely appeal to a Nasdaq Hearings Panel and requested a 180-day period to file and implement a compliance plan, which may include a reverse stock split if in shareholders' best interest.
The appeal automatically stays the determination until the hearing on December 18, 2025, and the company's ordinary shares will continue to trade as MLEC during the stay. The company said the letter does not affect its business operations or SEC reporting obligations.
Moolec Science (NASDAQ:MLEC), a biotechnology company focused on engineering plants and microbes for protein solutions, announced three significant developments. First, the company received regulatory approval from SENASA in Argentina for its safflower GLASO technology, enabling expansion of its GLA-enriched safflower crop production. Second, Moolec has doubled its U.S. safflower acreage compared to last year, strengthening its supply capabilities for the pet food and human nutrition markets.
Additionally, the company appointed Valeria Falottico as CFO, bringing over 20 years of financial expertise. Moolec also completed the integration of Mycofood™, its fungal-based protein platform, which is currently developing products for evaluation by food industry partners in North America and Europe.
Moolec Science (NASDAQ:MLEC) has announced a transformational all-stock Business Combination Agreement with Bioceres Group and other entities. The deal involves Moolec issuing up to 87 million new shares and 5 million warrants to acquire Bioceres Group, Nutrecon , and Gentle Technologies Corp.
The combined entity will control a portfolio of over 800 patents and 550 product registrations, representing more than half a billion dollars in annual sales across 50+ countries. The transaction positions Moolec as a comprehensive agricultural technology company, integrating molecular farming, biological inputs, and climate-resilient seeds.
Key highlights include:
- Continued development of molecular farming products (Piggy Sooy™, GLASO™)
- Integration of biological agricultural solutions through Bioceres Group
- Expansion into R&D and CDMO services under Agrality® and Synbio Powerlabs®
- Development of emerging technologies in biomaterials and farm equipment
Moolec Science SA (NASDAQ:MLEC) has received a Nasdaq Staff Determination Letter on March 11, 2025, indicating non-compliance with listing requirements as its stock price remained below $1.00 for over 30 consecutive business days since September 10, 2024. The company is not eligible for a second 180-day compliance period due to not meeting the $5,000,000 minimum stockholders' equity requirement.
On March 13, 2025, Moolec appealed the determination and plans to present a compliance strategy involving a reverse share split. The appeal temporarily halts any delisting actions. The Board of Directors has resolved to convene an extraordinary shareholders meeting to vote on the reverse share split. Without securing an extension from the Hearings Panel or achieving compliance, the company's ordinary shares and warrants face potential delisting from Nasdaq.
Moolec Science SA (NASDAQ:MLEC) has received USDA approval for the first genetically modified pea in history. The U.S. Department of Agriculture's Animal and Plant Health Inspection Service (APHIS) completed its Regulatory Status Review for Moolec's genetically engineered peas that produce iron through bovine meat proteins. This marks Moolec's third USDA-APHIS regulatory clearance in 18 months, following approvals for genetically engineered safflower and soybean.
The GE peas produce high yields of bovine myoglobin, boosting iron content and offering a plant-based iron source. This innovation has the potential to impact both the food ingredient market and the $65 billion pea industry. The approval validates Moolec's strategic approach and commitment to sustainable food production through science and innovation.
Moolec Science SA (NASDAQ:MLEC) reported its Business Update for Q4 FY2024 ended June 30, 2024. Key highlights include:
1. GLASO™: Secured an offtake agreement with a major global CPG food and pet food company and an R&D collaboration with Bunge. Significant advancements in upstream and downstream processes.
2. Piggy Sooy™: Field trials in three US locations progressing for product development, seed increase, and regulatory data gathering.
3. TSP Valorasoy™: Trials for enhanced Valorasoy 2.0 products showed encouraging results.
4. Financials: Revenue & other income of ~$6M for FY 2024, driven by soy protein ingredient business. Prudent cash burn in line with company growth.
The company highlighted the USDA-APHIS approval for PiggySooy™ as a pivotal moment in Molecular Farming. Moolec is preparing for the commercialization of GLASO™ and advancing its product pipeline.